Schizophrenia Market 2018 to Capture Double Digit CAGR By Diagnosis; Blood and Urine Tests, Brain Imaging, and Vision Testing | Forecast by MRFR Market Research Future published a research report on Global Schizophrenia Market and Provide detailed information on the possible segments and sub segments of the market and its regional analysis and Insights on the major countries in which this industry is blooming and to also identify the regions that are still untapped Schizophrenia is a chronic and severe mental disorder that affects the thinking, feeling, and behavior of the person. People with schizophrenia may be more in imagination world and lost touch with reality. Although schizophrenia is not as common as other mental disorders, the symptoms can be very disabling. The symptoms of this disease are categories in three way that are positive, negative, and cognitive. People with schizophrenia are more prone to die earlier than the normal population. This is often due to physical illnesses, such as cardiovascular, metabolic and infectious diseases. According to WHO, in 2016, More than 50% of people with schizophrenia are not receiving appropriate care. 90% of people with untreated schizophrenia live in low and developing countries, such as India, Pakistan, etc. Increasing prevalence of patients seeking treatment and rising demand for improved healthcare infrastructure are expected to drive the market. Moreover availability of funds and WHO initiative towards developing countries fuel the market in developing region. The Global Schizophrenia Market is expected to grow at a CAGR of 3.2% during the forecast period 2017-2023. Get Sample PDF Illustration https://www.marketresearchfuture.com/sample_request/1625
@
Key Players for Global Schizophrenia Market Market Research Future (MRFR) recognizes the following companies as the key players in Schizophrenia Market: There are plenty of large and small market players which operate in this market all over the globe. Minerva Neurosciences (U.S.), Promentis Pharmaceuticals, Inc. (U.S.), Bristol-Myers Squibb (U.S.), PsychoGenics Inc. (U.S.), Vineuro Pharmaceuticals, Novartis AG (Switzerland), Merz Pharma GmbH & Co. KGaA (Germany), AbbVie Inc. (U.S.), Eli-Lilly and Company (U.S.), AstraZeneca Plc (U.K) Segments for Global Schizophrenia Market The Global Schizophrenia Market is segmented on the basis of by diagnosis, by treatment type, and by end user. On the basis of the diagnosis, it is segmented into blood and urine tests, brain imaging, vision testing, and others. On the basis of the treatment type, it is segmented into surgery, radiation therapy, medications, and others. On the basis of the end user, it is segmented into hospitals, clinics, diagnostic centers, rehabilitation centers and others. Regional Analysis for Global Schizophrenia Market